NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.95, delivering a surprise of -97.92%.Over the last four quarters, the co ...